Selling stockholders may resell up to 8,934,345 Dare Bioscience common shares issuable under warrants, while the common warrants carry a $1.37 exercise price. Dare Bioscience would receive no proceeds from those resales, but cash exercises could generate up to approximately $12.4 million for working capital, research and development, and corporate purposes.
Key Highlights
- Common warrants carry a $1.37 exercise price, subject to customary adjustments.
- The registered shares include up to 8,759,162 shares tied to common warrants and 175,183 linked to Placement agent warrants.
- Lind Global Fund III LP could sell 2,189,780 shares, reducing its listed ownership from 12.68% to 2.66% if all registered shares are issued.
Dare Bioscience, Inc. (NASDAQ: DARE) registered the potential resale by selling stockholders of up to 8,934,345 common shares. The shares are issuable when holders exercise common warrants and placement agent warrants. Cash exercises could provide Dare Bioscience with up to approximately $12.4 million, while the company would receive no proceeds from the selling stockholders’ resales. The common warrants carry an exercise price of $1.37 per share, subject to customary adjustments for events including stock dividends, stock splits and rights offerings. The registered amount includes warrant-linked shares held by investors and placement agent-related parties.
Warrant-Linked Resale Shares
The registered total includes up to 8,759,162 shares issuable under Series A and Series B warrants. The common warrants require stockholder approval under Nasdaq rules before exercise. That approval had not been obtained as of the prospectus date, September 3, 2026. Series A warrants expire five years after the effective date of the required approval, while Series B warrants expire two years after that date.
Selling Holders’ Ownership
Lind Global Fund III LP is listed with beneficial ownership of 2,770,683 shares, or 12.68% of outstanding common stock, before the offering. Its maximum registered sale is 2,189,780 shares, leaving 580,903 shares and 2.66% ownership under the table’s assumptions. Armistice Capital Master Fund Ltd. and L1 Capital Global Opportunities Master Fund Ltd. are each listed with 2,189,780 shares and 10.02% ownership before the offering. Each may sell 2,189,780 shares under the registration. Nomis Bay Ltd. is listed with 1,357,690 shares and 6.46% ownership and may sell that full amount. BPY Limited is listed with 832,132 shares and 4.06% ownership and may also sell all 832,132 shares. The listed placement agent-related holders include Ladenburg Thalmann & Co. Inc. with 70,073 shares, Nicholas Stergis with 42,175, Meredith Sondler-Bazar with 26,277, David Coherd with 18,920, Andrew Moorefield with 9,460, Clesson Allman with 5,125 and Dan Daley with 3,153.
Dare Bioscience would receive proceeds only if the warrants are exercised for cash. The company expects to invest proceeds in interest-bearing marketable securities while awaiting deployment. Dare Bioscience will cover registration and filing fees, along with fees and expenses for its counsel and accountants. Selling stockholders will pay their own selling and other expenses.
Exercise Limits Remain
A holder generally cannot exercise a Warrant if doing so would raise its ownership above 4.99% immediately after exercise. Certain holders may use a 9.99% limit, and a holder may request an increase to that level with at least 61 days’ prior notice. The warrants may be exercised in whole or in part after approval by delivering an exercise notice and paying the exercise price. Cashless exercise is available when a registration statement covering the underlying shares is not effective or available. The selling stockholders may offer some, all or none of their warrant-linked shares. The company’s stated proceeds depend on cash exercises rather than the resale transactions themselves.




Please wait processing your request...